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Abstract: Ageing is associated with postprandial muscle vascular and metabolic dysfunction, suggest-
ing vascular modifying interventions may be of benefit. Reflecting this, we investigated the impact
of acute cocoa flavanol (450–500 mg) intake (versus placebo control) on vascular (via ultrasound) and
glucose/insulin metabolic responses (via arterialised/venous blood samples and ELISA) to an oral
nutritional supplement (ONS) in twelve healthy older adults (50% male, 72 ± 4 years), in a crossover
design study. The cocoa condition displayed significant increases in m. vastus lateralis microvascular
blood volume (MBV) in response to feeding at 180 and 240-min after ONS consumption (baseline:
1.00 vs. 180 min: 1.09 ± 0.03, p = 0.05; 240 min: 1.13 ± 0.04, p = 0.002), with MBV at these timepoints
significantly higher than in the control condition (p < 0.05). In addition, there was a trend (p = 0.058)
for MBV in m. tibialis anterior to increase in response to ONS in the cocoa condition only. Leg blood
flow and vascular conductance increased, and vascular resistance decreased in response to ONS
(p < 0.05), but these responses were not different between conditions (p > 0.05). Similarly, glucose
uptake and insulin increased in response to ONS (p < 0.05) comparably between conditions (p > 0.05).
Thus, acute cocoa flavanol supplementation can potentiate oral feeding-induced increases in MBV in
older adults, but this improvement does not relay to muscle glucose uptake.
Keywords: cocoa flavanols; blood flow; glucose metabolism; skeletal muscle; ageing
1. Introduction
Skeletal muscle is the largest organ system by mass in the body, and in being its
locomotory engine, largest amino acid reservoir, and main site of postprandial glucose
handling [1], represents an organ crucial to the maintenance of physical functioning and
metabolic health. Of the conditions associated with skeletal muscle deterioration, age-
related sarcopenia represents a global health problem, demonstrating robust associations
with risk of frailty [2], morbidity [3], and in extreme cases, mortality [4]. Ageing is also
the main risk factor for cardiovascular disease [5], with deterioration of vascular systems
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feeding directly into skeletal muscle implicated in sarcopenia [6]. Reflecting this, older
adults display reductions of ~20–30% in limb conduit artery blood flow compared to
younger counterparts [7,8], underpinned by reductions in capillary density and surface
area [9,10]. Additionally, reduced muscle microvascular blood flow is observed in response
to anabolic stimuli (e.g., feeding) [9,11], with nutrient-induced increases in whole-limb
perfusion being attenuated with age [8]. Such blunted micro- and macrovascular blood
flow responses are hypothesised to contribute to age-related “anabolic resistance” to
feeding, via the limited delivery and/or utility of insulin and amino acids by muscle [12].
Since vascular dysfunction appears to be a modifiable, rather than inevitable aspect of
chronological ageing [11] (as evidenced by the preservation and improvement in vascular
function in lifelong exercisers and those starting exercise training, respectively [13,14]),
determining therapeutic strategies for maintaining or even potentiating vascular responses
in older adults is of paramount importance for the maintenance of muscle mass and
reducing cardiovascular risk.
Flavanols, a sub-group of plant-derived phytochemicals found naturally occurring in
(but not limited to) chocolate and red wine, have gained increasing attention as a potentially
efficacious nutraceutical since it was shown that high intakes of cocoa were associated with
a lower incidence of vascular-related diseases [15]. Subsequently, numerous clinical trials
have shown that flavanol-rich cocoa improves vascular endothelial (dys)function in both
healthy cohorts [16] and in those with disease [17], purportedly due to, or at least in part,
increased nitric oxide synthase activity and thus bioactive nitric oxide [18]. To demonstrate,
cocoa flavanol-induced vasodilation in humans was reversed in the presence of the nitric
oxide synthase inhibitor, L-NAME [19]. Further confirming these findings, cocoa flavanols
increased circulating nitric oxide species (RXNO) in tandem with enhanced vasodilation,
which were both reversed by L-NAME [20]. In line with this, we have previously shown
that acute cocoa supplementation improved muscle vascular responsiveness to intravenous
nutrition in older men [21]. However, these results may not represent the effects of cocoa
when combined with oral feeding where additional factors such as gut hormones (e.g.,
incretins) may have an effect [21]. Indeed, demonstrating the potency of gut hormones
on these responses, the incretin hormone, glucagon-like peptide-1, has been shown to
markedly enhance postprandial microvascular perfusion [22]. As such, it is plausible that
cocoa supplementation to oral feeding may modulate vascular responses in older adults,
though this remains to be determined.
Importantly, enhanced vascular responses may translate to improved glucose metabolism.
This may occur via the greater insulin-mediated glucose delivery to, and utilisation by,
skeletal muscle which is typically attenuated as part of the insulin resistance that develops
with advancing age and has been shown to contribute to the development of sarcopenia [23].
Indeed, impaired glucose handling can be modified by nutraceutical intervention in the
presence of improved endothelial function [24]. In the context of cocoa flavanols, chronic
consumption has been shown to improve the metabolic profile of older adults via reductions
in insulin resistance [25], which may lead to increased glucose uptake as directly evidenced
in pre-clinical models using skeletal muscle cells [26]. Nonetheless, whether vascular
responses subsequently impact insulin kinetics and glucose uptake following acute cocoa
flavanol intake in healthy older adults remains poorly defined.
It is evident that even ostensibly healthy older adults exhibit reductions in aspects of
limb and muscle vascular function alongside impaired glucose handling. Therefore, the
aim of this study was to assess the impact of acute cocoa flavanol supplementation on oral
feeding-induced changes in; (i) macrovascular (limb) blood flow, (ii) muscle microvascular
blood flow, and (iii) metabolic responses, in healthy older adults.
2. Materials and Methods
2.1. Ethical Approval
This study was reviewed and approved by the University of Nottingham Faculty of
Medicine and Health Sciences Research Ethics Committee (2-1704) and was conducted in
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accordance with the Declaration of Helsinki. All study associated risks and procedures were
thoroughly explained to volunteers and written consent was obtained prior to participation.
This study was pre-registered at clinicaltrials.gov (NCT03213340).
2.2. Volunteers and Study Design
Healthy older adults (≥65 years) were recruited from the local community and/or
via an internal recruitment database for this randomised, single-blind, placebo-controlled,
crossover clinical trial. Volunteers were eligible for the study if they met all of the following
inclusion criteria, determined at an initial screening session: (i) ≥65 years of age; (ii) body
mass index between 18–30 kg/m2; (iii) free from active metabolic disease assessed by
past medical history and had a clinically normal blood profile (liver and kidney function;
complete blood count; HbA1c <6%); (iv) blood pressure <160/100 mmHg; and (v) able to
provide written informed consent. Volunteers were excluded if they: were unable to adhere
to the study protocol; performed regular formal exercise (or any other routine strenuous
physical activity) more than once a week; were smokers; had surgery within past 3 months;
had cerebrovascular disease or active cardiovascular, respiratory, inflammatory bowel or
renal disease; were taking beta-adrenergic blocking agents; had active malignancy or until
confirmed remission; had clotting dysfunction; had a history of deep vein thrombosis;
had significant musculoskeletal or neurological disorders; had a family history of early
(<55 years) death from cardiovascular disease; had known sensitivity to Sonovue™ contrast
agent; had known allergy or intolerance to any of the study ingredients; and/or were
regularly taking over the counter supplements containing cocoa flavanols. Volunteers also
completed a handgrip strength assessment and short physical performance battery during
this session.
After the screening session, for those volunteers who were deemed eligible, this study
included two experimental study visits, separated by a 10–15 day “wash-out” period
(Figure 1). Volunteers were instructed to refrain from heavy exercise for 48 h prior to
each study visit and from taking medications that may impact blood flow on the day
prior to and on the day of each study visit (e.g., angiotensin-converting enzyme inhibitors,
decongestants). On the day of testing, volunteers arrived fasted from the night before
(water ad libitum) and had lean leg mass measured via dual X-ray absorptiometry (DXA;
Luna Prodigy II; GE Medical Systems, Little Chalfont, Buckinghamshire, UK) (study visit
1 only), leg blood flow (LBF) measured via Doppler ultrasound (iU22; Philips Healthcare,
Reigate, UK), microvascular blood flow (MBF) measured via contrast-enhanced ultrasound
(CEUS; iU22) and a baseline blood sample taken. Volunteers were then provided with the
study supplement (cocoa or placebo) to consume orally. An oral nutritional supplement
(ONS) was consumed 30 min after the study supplement. Thereafter, Doppler ultrasound
measurements, CEUS measurements and blood samples were obtained periodically over
the subsequent ~4 h period. Volunteer characteristics are shown in Table 1.
Table 1. Volunteer characteristics (mean ± SD).
Parameter Volunteers (n = 12)
Gender (% M) 50
Age (years) 72 ± 4
Height (cm) 170.7 ± 6.8
Weight (kg) 74.0 ± 13.1
BMI (kg/m2) 25.3 ± 3.1
Lean mass (kg) 46.5 ± 8.4
Resting heart rate (bpm) 65 ± 8
Resting systolic blood pressure (mmHg) 129 ± 10
Resting diastolic blood pressure (mmHg) 78 ± 8
Grip strength (kg) * 30.14 ± 7.79
SPPB 10 ± 1.1
BMI, body mass index; SPPB, short physical performance battery. * n = 11.





Figure 1. Schematic representation of the study protocol for experimental study visits 1 and 2. Twelve healthy older adults 
were studied in a crossover design in the fasted state, and with and without cocoa flavanols in the fed state (via oral 
nutritional supplement). * indicates assessment was carried out during study visit 1 only, ^ indicates that the first blood 
draw occurred 15 min after mixed meal feeding. CEUS, contrast-enhanced ultrasound; DXA, dual-energy X-ray absorp-
tiometry; ONS, oral nutritional supplement; US, ultrasound. 
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Parameter Volunteers (n = 12) 
Gender (% M) 50 
Age (years) 72 ± 4 
Height (cm) 170.7 ± 6.8 
Weight (kg) 74.0 ± 13.1 
BMI (kg/m2) 25.3 ± 3.1 
Lean mass (kg) 46.5 ± 8.4 
Resting heart rate (bpm) 65 ± 8 
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2.3. Study Supplements and ONS Feeding 
Volunteers were randomly assigned to receive either the cocoa or placebo supple-
ment in a crossover design. The placebo supplement was 33 g of low flavanol white choc-
olate chips (Blommer Royal, East Greenville, PA USA) providing <50 mg flavanols (con-
trol). The cocoa supplement was 33 g of high flavanol cocoa chips (Acticoa, Barry 
Callebaut, Lebbeke-Wieze, Belgium) proving 450–500 mg cocoa flavanols (cocoa). The 
450–500 mg dose was chosen as it is similar to the acute dose previously shown to elicit 
favourable changes in cardiovascular function indices [27,28] and blood flow responses 
[21]. Moreover, the chosen dose closely represents the dose given chronically, which has 
been shown to improve endothelial function [29]. Supplements were isocaloric and 
matched for taste and appearance. Exactly 30 min after consuming the supplement, vol-
unteers consumed 118 mL of ONS (Ensure Advance Vanilla, Abbott, North Chicago, IL, 
USA) providing 175 kcal, 7.5 g protein, 24 g carbohydrate and 6 g fat, in order to investi-
gate whether cocoa flavanols can enhance vascular responses beyond those achieved with 
mixed macronutrient oral feeding. 













Figure 1. Schematic representation of the study protocol for experimental study visits 1 and 2. Twelve healthy older
adults were studied in a crossover design in the fasted state, and with and without cocoa flavanols in the fed state (via
oral nutritional supplement). * indicates assessment was carried out during study visit 1 only, ˆ indicates that the first
blood draw occurred 15 min after mixed meal feeding. CEUS, contrast-enhanced ultrasound; DXA, dual-energy X-ray
absorptiometry; ONS, oral nutritional supplement; US, ultrasound.
2.3. Study Supplements and ONS Feeding
Volunteers were randomly assigned to receive either the cocoa or placebo supplement
in a crossover design. The placebo supplement was 33 g of low flavanol white chocolate
chips (Blommer Royal, East Greenville, PA, USA) providing <50 mg flavanols (control).
The cocoa supplement was 33 g of high flavanol cocoa chips (Acticoa, Barry Callebaut,
Lebbeke-Wieze, Belgium) proving 450–500 mg cocoa flavanols (cocoa). The 450–500 mg
dose was chosen as it is similar to the acute dose previously shown to elicit favourable
changes in cardiovascular function indices [27,28] and blood flow responses [21]. Moreover,
the chosen dose closely represents the dose given chronically, which has been shown to
improve endothelial function [29]. Supplements were isocaloric and matched for taste and
appearance. Exactly 30 min after consuming the supplement, volunteers consumed 118 mL
of ONS (Ensure Advance Vanilla, Abbott, North Chicago, IL, USA) providing 175 kcal, 7.5 g
protein, 24 g carbohydrate and 6 g fat, in order to investigate whether cocoa flavanols can
enhance vascula re po ses beyond those achieved with mixed macronutrient oral feeding.
2.4. Measurement of LBF Using Doppler Ultrasound
LBF was measured by Doppler ultrasound (iU22 ultrasound scanner, Phillips Health-
care, Reigate, Surrey, UK), as prev ously described [30]. In brief, a L17-5 MHz probe
was positioned over the left common femoral artery to facilitate the assessment of LBF
as vessel cross-sectional area x mean velocity, over 6 cardiac cycles. Ultrasound gel was
used to enhance the ultrasound signal, with all measurements taken with the volunteer
supine with no visual or aural stimuli. A mean of three measurements was made at each
timepoint, distributed across the study period. LBF was adjusted to lean leg mass for each
volunteer and standardised to fasting LBF. Leg vascular conductance (LVC) was calculated
as: LBF/mean arterial pressure (which was calculated as: (2/3 diastolic blood pressure) +
(1/3 systolic blood pressure)) and leg vascular resistance (LVR) was calculated as: mean
arterial pressure/LBF, as described previously [12,31].
2.5. Measurement of MBF Using CEUS
CEUS permitted the measurement of changes in MBF and its components: microvascu-
lar blood volume (MBV) and microvascular flow velocity (MFV). As previously described
in detail [32], a iU22 ultrasound scanner (Phillips Healthcare, Reigate, Surrey, UK) was
used to detect Sonovue™ microbubbles (Bracco, Milan, Italy), which were infused via an
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antecubital fossa vein. Briefly, one linear probe was positioned on the m. vastus lateralis and
another on the m. tibialis anterior to detected intravascular microbubble concentration in
both upper and lower leg muscles. Intermittent high mechanical index “flashes” were used
to disrupt microbubbles, with subsequent continuous low mechanical index recording
measuring the rate of microbubble reappearance after each flash. Sonovue™ was first
infused at 2 mL/min for 1 min and then 1 mL/min for 3 min thereafter. At 2.5 min 3–30 s
flash/replenishment recordings were made across the last 90 s of this protocol at each CEUS
timepoint. After each flash, a 0.48 s window was used to adjust for non-contrast signal
and for rapid filling of larger conduit (non-exchange) vessels. The acoustic intensity of the
insonated tissue in the post-flash period demonstrates a first order exponential association
function with a rate constant that is proportional to MFV and a plateau proportional to
MBV. For each CEUS measurement volunteers were asked to rest still and quiet, with each
measurement lasting <10 min.
2.6. Blood Sampling
Glucose uptake/release was assessed using an Arterio-Venous (A-V) sampling ap-
proach, by measuring blood glucose concentrations (Glucose Analyzer, YSI, Yellow Springs)
across the leg by sampling arterial and venous bloods (using the Fick Principle) [33]. Plasma
insulin concentrations was measured using a high sensitivity human insulin enzyme-linked
immunosorbent assay (ELISA; DRG Instruments GmbH, Marburg, Germany) according
to manufacturer’s instruction. Total insulin responses to feeding for each volunteer was
calculated using the area under the insulin concentration/time curve above baseline (with
baseline equal to insulin concentration measured before feeding).
2.7. Statistical Analysis
Two-way repeated measures ANOVA with Dunnett’s multiple comparison analysis
was used to determine time x supplement effects. CEUS data was normalised to baseline to
allow comparison between conditions. Two-way repeated measures ANOVA with Sidak’s
post hoc analysis was used to compare condition differences. Blood glucose A-V balance
and insulin data were analysed by area under the curve (AUC) with paired t-tests used
to determine supplement effects. Data were accepted as significant if p < 0.05. Trends
were reported and interpreted with caution if p < 0.10. Data analysis was conducted using
GraphPad Prism version 8 (GraphPad Software, San Diego, CA). Data are presented as
mean ± SEM (unless otherwise stated).
3. Results
3.1. LBF, LVC and LVR
LBF significantly increased from baseline in both conditions early in the fed phase
(cocoa: 0 min: 297.70 ± 38.17 vs. 25 min: 416.89 ± 40.08 mL/min, p = 0.001; control:
0 min: 247.19 ± 27.77 vs. 25 min: 351.23 ± 38.53 mL/min, p = 0.007), returning to
basal levels by 85 min in the cocoa condition, and by 175 min in the control condition
(Figure 2A). Interestingly, compared to baseline there was a second increase in LBF in the
cocoa condition at 235 min (0 min: 297.70 ± 38.17 vs. 235 min: 402.58 ± 47.52 mL/min,
p = 0.007) (Figure 2A). Similar to LBF, LVC significantly increased from baseline in both
conditions early in the fed phase (cocoa: 0 min: 3.08 ± 0.37 vs. 25 min: 4.88 ± 0.48 mL/min,
p = 0.007; control: 0 min: 2.63 ± 0.30 vs. 25 min: 4.09 ± 0.42 mL/min, p = 0.007), again
returning to basal values by 85 min in the cocoa condition and by 175 min in the control
condition (Figure 2B). LVR was significantly decreased at all timepoints in both conditions,
except at 115, 175 and 205 min in the cocoa condition (Figure 2C). There were no significant
differences between conditions at any timepoint for any Doppler-based measurements.
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3.2. MBF 
CEUS measurements were performed on the m. vastus lateralis and m. tibialis anterior 
of healthy older adults to determine the effects of acute cocoa flavanol supplementation 
on MBV, MFV and their product MBF in muscles that differ in both location (proximal vs. 
distal, respectively), size (larger vs. smaller, respectively) and fibre type composition 
(equal type I:II ratio vs. predominantly type I, respectively). In the m. vastus lateralis, the 
cocoa condition demonstrated a significant increase in MBV responses to an ONS at 180 
and 240 min post-feeding compared to baseline (baseline: 1.00 vs. 180 min: 1.09 ± 0.03, p = 
0.05; 240 min: 1.13 ± 0.04, p = 0.002) with MBV at these timepoints significantly higher than 
those observed in the control condition (180 min: cocoa: 1.09 ± 0.03 vs. control: 0.99 ± 0.03, 
p = 0.033; 240 min: cocoa: 1.13 ± 0.04 vs. control: 1.02 ± 0.04, p = 0.021) (Figure 3A). Interest-
ingly, the increase in MBV at 240 min closely coincided with the secondary increase in 
LBF seen in the cocoa condition (Figure 2A). In the control condition, there was no signif-
icant change in MBV from baseline over time. MFV and MBF did not change over time 
within the cocoa or control condition and no significant differences were detected between 
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conductance (B) or vascular resistance (C) of healthy older adults. ˆ denotes significant within condition difference from
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3.2. MBF
CEUS measurements were performed on the m. vastus lateralis and m. tibialis anterior
of healthy older adults to determine the effects of acute cocoa flavanol supplementation
on MBV, MFV and their product MBF in muscles that differ in both location (proximal vs.
distal, respectively), size (larger vs. smaller, respectively) and fibre type composition (equal
type I:II ratio vs. predomin ntly type I, resp ctiv ly). In the m. vastus lat ralis, the cocoa
condition demonstrated a signific t increase in MBV responses to an ONS at 180 and
240 min post-feeding compared to baseline (baseline: 1.00 vs. 180 min: 1.09 ± 0.03, p = 0.05;
240 min: 1.13 ± 0.04, p = 0.002) with MBV at these timepoints significantly higher than
those observed in the control condition (180 min: cocoa: 1.09 ± 0.03 vs. control: 0.99 ± 0.03,
p = 0.033; 240 min: cocoa: 1.13 ± 0.04 vs. control: 1.02 ± 0.04, p = 0.021) (Figure 3A).
Interestingly, the increase in MBV at 240 min closely coincided with the secondary increase
in LBF seen in the cocoa condition (Figure 2A). In the control condition, there was no
significant change in BV from baseline over time. MFV and MBF did not change over
tim within the cocoa or control condition and no significant differences were detected
betwee the conditions (Figure 3B,C).




Figure 3. Cocoa enhanced oral nutritional supplement feeding-induced changes in microvascular blood volume (A) but 
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In the m. tibialis anterior, MBV, MFV and MBF did not change over time within the 
cocoa or control condition and there were no significant differences between the condi-
tions (Figure 3D–F). However, there was a trend for increased MBV in the cocoa condition 
at 240 min post-meal (baseline: 1.00 vs. 240 min: 1.06 ± 0.03, p = 0.058), which was not 
observed in the control condition (Figure 3D). 
3.3. Blood Glucose and Insulin 
Arterial and venous glucose both significantly increased in the early post-feeding 
phase in both the cocoa and control condition, which was expedited compared to the con-
trol condition, and returned to baseline by 185 min (Figure 4A,B). No significant difference 
was observed between the conditions at any timepoint except for arterial glucose at 15 
min, which was higher in the control condition (Figure 4A). Arterial and venous AUC was 
not different between conditions (data not shown). Glucose A-V balance increased at 15 
(0 min: 0.18 ± 0.02 vs. 15 min: 0.41 ± 0.05 mmol, p = 0.009) and 35 min (0 min: 0.18 ± 0.02 vs. 
35 min: 0.40 ± 0.05 mmol, p = 0.026) in the control conditions only, however, there was no 
significant differences between conditions for glucose A-V balance at any timepoint (Fig-
ure 4C), or for glucose AUC (data not shown). Glucose uptake increased in both condi-
tions at 35 min (cocoa: 0 min: 0.04 ± 0.01 vs. 35 min: 0.13 ± 0.02 mmol/min/leg, p = 0.021; 
control: 0 min: 0.04 ± 0.01 vs. 35 min: 0.12 ± 0.01 mmol/min/leg, p = 0.012) and remained 
elevated only in the cocoa condition at 65 and 95 min (0 min: 0.04 ± 0.01 vs. 65 min: 0.14 ± 
0.02 mmol/min/leg, p = 0.011; vs. 95 min: 0.12 ± 0.02 mmol/min/leg, p = 0.041), however, 
there was no significant difference between conditions at any time point for glucose up-
take (Figure 4D) or glucose uptake AUC (data not shown). As expected, insulin signifi-
cantly increased from baseline both conditions early post-feeding, returning to basal val-
ues by 185 min in the control condition and 215 min in the cocoa condition (Figure 4E). 
There was no significant difference between the conditions at any timepoint in insulin, or 




















































































































































































































Figure 3. Cocoa enhanced oral nutritional supplement feeding-induced changes in microvascular blood volume (A) but not
microvascular flow velocity (B) or microvascular blood flow (C) in the m. vastus lateralis and did not influence microvascular
perfusion of the m. tibialis anterior (D–F) of healthy older adults. ~ denotes a significant difference between conditions
(p < 0.05); * denotes significant within condition difference from cocoa baseline (p < 0.05).
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In the m. tibialis anterior, MBV, MFV and MBF did not change over time within the
cocoa or control condition and there were no significant differences between the conditions
(Figure 3D–F). However, there was a trend for increased MBV in the cocoa condition at
240 min post-meal (baseline: 1.00 vs. 240 min: 1.06 ± 0.03, p = 0.058), which was not
observed in the control condition (Figure 3D).
3.3. Blood Glucose and Insulin
Arterial and venous glucose both significantly increased in the early post-feeding
phase in both the cocoa and control condition, which was expedited compared to the control
condition, and returned to baseline by 185 min (Figure 4A,B). No significant difference was
observed between the conditions at any timepoint except for arterial glucose at 15 min,
which was higher in the control condition (Figure 4A). Arterial and venous AUC was not
different between conditions (data not shown). Glucose A-V balance increased at 15 (0 min:
0.18 ± 0.02 vs. 15 min: 0.41 ± 0.05 mmol, p = 0.009) and 35 min (0 min: 0.18 ± 0.02 vs.
35 min: 0.40 ± 0.05 mmol, p = 0.026) in the control conditions only, however, there was
no significant differences between conditions for glucose A-V balance at any timepoint
(Figure 4C), or for glucose AUC (data not shown). Glucose uptake increased in both
conditions at 35 min (cocoa: 0 min: 0.04 ± 0.01 vs. 35 min: 0.13 ± 0.02 mmol/min/leg,
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changes did not translate into improved glucose/insulin responses. 
Our primary finding was that acute cocoa flavanol supplementation may overcome 
age-related vascular dysfunction in the postprandial state (in the context of the m. vastus 
lateralis), suggesting that the impact of cocoa flavanols goes beyond the effect of the feed-
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As enhanced MBV is observed following acute cocoa supplementation, and since we have 
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4. Discus ion
We investigated if acute cocoa flavanol supplementation coupled to oral feeding
would modify micro- and macrovascular responses in the leg, and subsequent metabolic
responses, in healthy older adults. We found that acute supplementation of cocoa flavanols
increased micro- but not macrovascular responses to ONS; these microvascular changes
did not translate into improved glucose/insulin responses.
Our primary finding was that acute cocoa flavanol supplementation may overcome age-
related vascular dysfunction in the postprandial state (in the context of the m. vastus lateralis),
suggesting that the impact of cocoa flavanols goes beyond the effect of the feeding-related
insulin response, which alone is known to enhance microvascular flow [34]. As enhanced
MBV is observed following acute cocoa supplementation, and since we have found plasma
epicatechin to peak 2 h following coc a flavanol consumption (baseli e: n e detected,
2 h: 0.21 ± 0.06 µM, undet table following placebo), it is likely that increased bioactive
nitric xide availability underlie these changes [19]. Int restingly, incre s s in MBV were
only observed later in the postprandial period (180 and 240 min), yet in a previous study,
we observed that net essential amino acid (EAA) uptake had returned to fasting levels
by 180–240 min [35]. It is possible that the observed changes in MBV reflect late capillary
recruitment and may not impact EAA-induced increases in muscle protein synthesis. This
notion is supported by our previous work which found acute cocoa flavanols increased
MBV in the muscles of older men when administered with an intravenous infusion of
amino acids, but this did not translate into augmented protein accretion [21]. As such,
the physiological impacts of enhanced acute vascular responses, as seen following cocoa
supplementation, remain to be determined. It is plausible that these vascular responses
can lead to increased nutrient (and oxygen) delivery to the muscle, laying the foundations
for longer-term adaptations with chronic supplementation. In support of this, chronic
flavanol supplementation has been shown to (i) improve exercise capacity, accompanied
by enhanced oxidative capacity and angiogenesis (albeit in a pre-clinical model) [36];
(ii) improve mitochondrial structure and biogenesis in type II diabetic and heart failure
patients [37]; and (iii) improve capillary density in individuals with peripheral artery dis-
ease [38]. Therefore, we anticipate that cocoa supplementation has important physiological
consequences beyond acute anabolism, which require further investigation in the form of
chronic supplementation human trials.
To our knowledge, this is the first trial to assess the impacts of acute cocoa flavanol
supplementation in both the m. vastus lateralis and the m. tibialis anterior. Whilst previous
studies in humans have started to unravel cocoa flavanol-induced impacts on muscle
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perfusion, to date they have mainly focused on the m. vastus lateralis; a proximal muscle
that displays a roughly equal fibre type split [39]. Currently, little is known about more
distal, oxidative, capillary-dense muscles such as m. tibialis anterior [40], which is composed
of ~70% type I fibres, irrespective of gender [41]. Considering the greater capillarisation of
the m. tibialis anterior, it is plausible that cocoa flavanols may be beneficial in such muscles
due to the potential for greater capillary recruitment and thus greater delivery of insulin
and amino acids. Functionally, the m. tibialis anterior is the primary ankle dorsiflexor
underpinning everyday activities, such as gait and balance when walking [41], which are
increasingly important during ageing and strongly associate with the occurrence of falls [42].
Therefore, the ability to improve the vascular profile of lower limb muscles, alongside upper
limb muscles, could have significant ramifications for whole limb functionality/muscle
health in ageing populations. Considering that we found a trend (p = 0.06) towards
increased MBV at 240 min in the cocoa condition only is suggestive that cocoa may also
increase late capillary recruitment within the m. tibialis anterior. That these effects appear to
be attenuated in comparison to those seen in the m. vastus lateralis may be due to its smaller
size and thus absolute vascular network size, rendering potentially impactful changes
smaller, and therefore harder to detect, compared to the larger m. vastus lateralis.
As well as MBV, CEUS also permits the measurement of other vascular components,
namely microvascular blood flow velocity (i.e., MFV) and the combined product of MBV
and MFV that is MBF [11]. We found that neither ONS or ONS plus cocoa flavanols
had any impact on MFV, and despite changes in MBV, MBF did not change in either
m. vastus lateralis or m. tibialis anterior. Seeing as MFV is dependent on the dilation of
the resistance arterioles that are upstream of the terminal arterioles and capillaries, it is
plausible that longer term supplementation protocols are needed to reveal the effect of
cocoa flavanols on MFV and MBF. In addition, it should be noted that it is MBV that
has been shown, since the classical studies of August Krogh, to be associated with tissue
metabolism [43,44] and confirmed to represent capillary perfusion [44,45].
Despite cocoa-specific impacts on MBV, LBF (i.e., macrovascular blood flow) increased
similarly in the cocoa and control conditions, indicating that LBF is primarily driven by the
insulin response to ONS and cannot be further potentiated by acute cocoa flavanol intake.
However, it is not wholly surprising that MBV does not change proportionally to LBF as
the two have been previously shown not to correlate [34], and changes in MBV can occur
with little change in LBF [46]. Indeed, the insulin-mediated (i.e., via the ONS) decrease
in LVR and increase in LVC observed in both the cocoa and control conditions are the
probable primary drivers behind augmented LBF [47]. Although somewhat speculative,
we observed an identical temporal response in LBF and LVC, which may suggest that
LVC is the critical determinant of the LBF response (compared with LVR), however, this
requires further validation. Further, although ONS stimulated beneficial responses in
LVC and LVR, these were not potentiated by acute cocoa flavanols, suggesting chronic
cocoa supplementation is required to drive LBF, LVC and LVR adaptations. In support of
this, numerous chronic studies in the literature have reported beneficial macrovascular
outcomes in young [48] and middle-aged [28] healthy adults after cocoa supplementation,
with chronic investigation in healthy older adults still required.
We also determined whether cocoa-induced improvements in vascular responses
translated into improved insulin/glucose metabolic responses; a hypothesis worthy of
investigation since chronic intake of high dose cocoa flavanols can improve metabolic
outcomes in type II diabetics [49]. Despite a valid rationale and the observed increase in
MBV, although plasma insulin increased following ONS, there were no temporal differences
between the cocoa and control condition. This suggests that a further increase in insulin is
not required for potentiated MBV responses, supporting our previous work which also
found no differences in plasma insulin or proximal insulin signalling following acute cocoa
supplementation [21]. Similarly, the increase in glucose uptake following ONS was similar
between conditions and therefore not potentiated by cocoa flavanols. Seeing as muscle
glucose uptake is driven by insulin, the similar insulin responses between conditions
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may explain comparable glucose uptake levels. As insulin and glucose kinetics were
similar between the cocoa and control conditions in this acute study, it is likely that it
is the cumulative effect of cocoa flavanols (i.e., chronic supplementation) that elicits the
previously observed favourable metabolic responses (e.g., [49]), and thus this form of
supplementation regime requires testing in older healthy (i.e., non-diabetic) adults, who as
a consequence of advancing age are at heightened risk of cardiometabolic disease [50].
Regarding potential study limitations, although this study recruited older adults to
investigate the impact of cocoa flavanols on aspects related to age-related comorbidities,
we acknowledge that by using healthy older adults our volunteer pool may not be truly
representative of the older adult population as a collective, given the known prevalence
of comorbidities and associated polypharmacy in older age [51]. Additionally, our study
sample (n = 12) may be considered small and so larger clinical trials are needed to confirm
the vascular-promoting effects of cocoa flavanols in larger cohorts. Nonetheless, our study
is strengthened by the crossover design, which allows volunteers to serve as their own
control therein minimising the influence of confounding factors (e.g., body mass), thus
requiring smaller volunteer numbers to achieve sufficient power compared to parallel
study designs [52,53]. Further, post hoc power calculation using the current dataset output
power as >0.8, suggesting our sample size was sufficient to detect statistical significance.
Furthermore, studies investigating blood flow responses in young [54] and older [7] adults
have used fewer volunteers than herein (i.e., n = 6–8).
5. Conclusions
To conclude, we show that acute cocoa flavanol supplementation can potentiate
ONS feeding-induced increases in MBV in healthy older adults, but this improvement
does not translate to enhanced glucose/insulin metabolism. The acute cocoa flavanols
provided during this study were consumed orally and were well-tolerated by all volunteers,
suggesting that cocoa flavanols may be an efficacious and safe nutraceutical intervention
for increasing muscle blood flow, and thus nutrient and oxygen delivery, in older adults.
Larger clinical trials investigating the effects of acute and chronic cocoa supplementation
should be conducted to confirm these findings, and the potential physiological impact, in
older adults before recommending cocoa flavanols as vascular promoting nutraceuticals.
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